Assenagon Asset Management S.A. Sells 217,594 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Assenagon Asset Management S.A. lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 62.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 132,458 shares of the biotechnology company's stock after selling 217,594 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.14% of Sarepta Therapeutics worth $16,106,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. raised its position in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares in the last quarter. Huntington National Bank increased its stake in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 175 shares during the period. Nkcfo LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth about $43,000. UMB Bank n.a. increased its stake in Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 197 shares during the period. Finally, Values First Advisors Inc. acquired a new position in shares of Sarepta Therapeutics in the 3rd quarter worth approximately $59,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm's stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company's stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded up $0.94 during trading on Friday, reaching $118.00. 649,119 shares of the company's stock traded hands, compared to its average volume of 566,751. The firm's 50-day moving average is $121.61 and its 200 day moving average is $129.70. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 1 year low of $102.15 and a 1 year high of $173.25. The company has a market capitalization of $11.27 billion, a P/E ratio of 94.40 and a beta of 0.77.

Analysts Set New Price Targets

Several brokerages recently issued reports on SRPT. Evercore ISI reduced their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research report on Thursday, November 7th. Royal Bank of Canada reiterated an "outperform" rating and set a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Guggenheim increased their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Robert W. Baird decreased their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. Finally, Needham & Company LLC reissued a "buy" rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $178.71.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.